News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
895,577 Results
Type
Article (89566)
Company Profile (591)
Press Release (805401)
Multimedia
Podcasts (279)
Webinars (42)
Section
Business (267440)
Career Advice (4176)
Deals (40145)
Drug Delivery (235)
Drug Development (92088)
Employer Resources (212)
FDA (18714)
Job Trends (17552)
News (399523)
Policy (40038)
Tag
2025 Best Places to Work (2)
2026 Best Places to Work (3)
2027 BioCapital Elite (1)
2027 BioCapital Standard (6)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (15)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (3)
2027 Biotech Beach Standard (9)
2027 Genetown Digital (6)
2027 Genetown Elite (6)
2027 Genetown Premier (1)
2027 Genetown Standard (12)
2027 NextGen (20)
2027 Pharm Country Digital (8)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (10)
40 Under 40 (2)
Academia (3104)
Academic (2)
Accelerated approval (74)
ADA (53)
Adcomms (44)
Allergies (231)
Alliances (56997)
ALS (285)
Alzheimer's disease (2117)
Antibody-drug conjugate (ADC) (757)
Approvals (19287)
Artificial intelligence (1122)
ASCO (350)
Autoimmune disease (500)
Automation (80)
Bankruptcy (412)
Belgium (36)
Best Places to Work (12635)
BIO (81)
Biologics (85)
BIOSECURE Act (23)
Biosimilars (302)
BioSpace Insights (266)
Biotechnology (340)
Bispecific (44)
Bladder cancer (244)
Brain cancer (101)
Breast cancer (961)
Cancer (7851)
Cardiovascular disease (660)
Career advice (3636)
Career pathing (65)
CAR-T (452)
CDC (82)
CDMO (220)
Celiac Disease (7)
Cell-line development (2)
Cell therapy (1244)
Cervical cancer (66)
Clinical research (80921)
Collaboration (2828)
Commercialization (57)
Company closure (10)
Compensation (1875)
Complete response letters (126)
COVID-19 (3074)
CRISPR (147)
CRO (4)
C-suite (1679)
Cystic fibrosis (182)
Data (10636)
Decentralized trials (4)
Denatured (110)
Depression (224)
Dermatology (189)
Diabetes (838)
Diagnostics (7905)
Digital health (83)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (555)
Drug pricing (253)
Drug shortages (40)
Duchenne muscular dystrophy (380)
Earnings (104076)
Editorial (85)
Employer branding (27)
Employer resources (184)
ESMO (432)
Events (141273)
Executive appointments (1371)
Eye disease (17)
FDA (23724)
Fibrodysplasia Ossificans Progressiva (16)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (42)
Funding (2331)
Gene editing (313)
Generative AI (113)
Gene therapy (971)
GLP-1 (1387)
Government (5627)
Grass and pollen (8)
Guidances (439)
Healthcare (21436)
Hematology (205)
HIV (121)
Huntington's disease (86)
Idiopathic pulmonary fibrosis (15)
IgA nephropathy (154)
Immunology and inflammation (424)
Immuno-oncology (159)
Indications (286)
Infectious disease (3528)
Inflammatory bowel disease (279)
Inflation Reduction Act (17)
Influenza (164)
Intellectual property (379)
Interviews (829)
IPO (18067)
IRA (61)
Job creations (5211)
Job search strategy (2882)
JPM (73)
Kidney cancer (31)
Kidney disease (169)
Labor market (148)
Layoffs (726)
Leadership (69)
Legal (10180)
Licensing (97)
Liver cancer (119)
Longevity (56)
Lung cancer (1086)
Lung diease (22)
Lymphoma (545)
Machine learning (78)
Management (72)
Manufacturing (1620)
Marketing (33)
MASH (249)
Medical affairs (5)
Medical device (15467)
Medtech (15782)
Mergers & acquisitions (23599)
Metabolic disorders (2109)
mRNA (333)
Multiple sclerosis (253)
Multispecific (6)
NASH (24)
Netherlands (32)
Neurodegenerative disease (620)
Neuropsychiatric disorders (151)
Neuroscience (4265)
Neurotech (4)
NextGen: Class of 2026 (7717)
Non-profit (5173)
Now hiring (100)
Obesity (993)
Opinion (405)
Ovarian cancer (295)
Pain (347)
Pancreatic cancer (448)
Parkinson's disease (487)
Partnered (52)
Patents (799)
Patient advocacy (6)
Patient recruitment (984)
Patient selection (92)
Peanut (77)
People (69060)
Peptides (29)
Pharmaceutical (83)
Pharmacy benefit managers (42)
Phase 1 (24954)
Phase 2 (35121)
Phase 3 (26505)
Pipeline (13745)
Policy (426)
Postmarket research (3561)
Preclinical (11152)
Press Release (74)
Prostate cancer (406)
Psychedelics (96)
Radioligand (3)
Radiopharmaceuticals (441)
Rare diseases (1573)
Real estate (7478)
Recruiting (84)
Regenerative medicine (29)
Regulatory (31740)
Reports (96)
Research institute (2815)
Resumes & cover letters (656)
Rett syndrome (59)
RNA editing (39)
RSV (105)
Schizophrenia (224)
Series A (401)
Series B (278)
Service/supplier (16)
Sickle cell disease (142)
Special edition (36)
Spinal muscular atrophy (201)
Sponsored (61)
Startups (4400)
State (2)
Stem cells (6)
Stomach cancer (24)
Substance use disorders (22)
Supply chain (169)
Switzerland (9)
Tariffs (107)
Tax incentives (2)
The Weekly (166)
Vaccines (1427)
Venture capital (175)
Weight loss (665)
Wet AMD (7)
Women's health (188)
Women in leadership (1)
Worklife (28)
Date
Today (202)
Last 7 days (868)
Last 30 days (3281)
Last 365 days (34012)
2026 (28242)
2025 (33212)
2024 (37831)
2023 (42564)
2022 (53927)
2021 (58720)
2020 (57662)
2019 (51334)
2018 (39119)
2017 (37187)
2016 (38329)
2015 (44431)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1309)
Alabama (116)
Alaska (7)
Arizona (477)
Arkansas (17)
Asia (53089)
Australia (9346)
California (16775)
Canada (4661)
China (2001)
Colorado (738)
Connecticut (747)
Delaware (529)
Europe (122523)
Florida (2551)
Georgia (549)
Hawaii (5)
Idaho (70)
Illinois (1466)
India (148)
Indiana (771)
Iowa (35)
Japan (760)
Kansas (156)
Kentucky (68)
Louisiana (70)
Maine (97)
Maryland (1991)
Massachusetts (12149)
Michigan (471)
Minnesota (926)
Mississippi (8)
Missouri (185)
Montana (37)
Nebraska (31)
Nevada (193)
New Hampshire (94)
New Jersey (4437)
New Mexico (38)
New York (4387)
North Carolina (2187)
North Dakota (13)
Northern California (8536)
Ohio (530)
Oklahoma (32)
Oregon (53)
Pennsylvania (3214)
Puerto Rico (37)
Rhode Island (63)
South America (1673)
South Carolina (103)
South Dakota (2)
Southern California (6667)
Tennessee (280)
Texas (2785)
United States (59610)
Utah (510)
Vermont (2)
Virginia (431)
Washington D.C. (88)
Washington State (1351)
West Virginia (4)
Wisconsin (193)
Wyoming (6)
895,577 Results for "%E2%80%9D%20target=".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gossamer Bio Announces 1-for-80 Reverse Stock Split - September 9, 2026
September 9, 2026
·
6 min read
Press Releases
Kovina Therapeutics Awarded $2.3 Million NCI Grant to Advance First-in-Class HPV Cancer Therapy Directly Targeting E6
September 24, 2026
·
2 min read
Press Releases
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
August 10, 2026
·
7 min read
Press Releases
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
September 30, 2026
·
4 min read
Cancer
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
Bristol Myers Squibb acquired the degrader-antibody conjugate from Orum Therapeutics in 2023 for $100 million upfront and the possibility of up to $80 million more in milestones.
September 18, 2026
·
1 min read
·
Tristan Manalac
Sponsored by Sino Biological
From cells to organoids: Cytokines that shape 3D culture
High-quality cytokines for organoid growth, differentiation, and expansion.
October 19, 2026
·
7 min read
·
Mengtong Cao, Ph.D.
Mergers & acquisitions
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and autoimmune diseases.
August 31, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
July 28, 2026
·
6 min read
ALS
Novartis halts TREM2 targeting ALS program in 4th
trial stumble in a month
The TREM2 stabilizer failed to show efficacy in a Phase 2 trial of patients with early-stage ALS. This development follows two late-stage trial failures reported by Novartis last week, plus the news that the pharma has paused multiple CAR T cell trials following patient deaths.
September 16, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Life Biosciences Secures $80 Million Series D Financing
April 8, 2026
·
3 min read
1 of 89,558
Next